Account subscription benefits alongside Premium Stories, Editorials,
\n Opinions and more. Unlock these with Subscription<\/p>\n
The View From India
\n\t\t\t\t\t\t\t\t\tLooking at World Affairs from the Indian perspective.<\/p>\n
First Day First Show
\n\t\t\t\t\t\t\t\t\tNews and reviews from the world of cinema and streaming.<\/p>\n
Today's Cache
\n\t\t\t\t\t\t\t\t\tYour download of the top 5 technology stories of the day.<\/p>\n
Science For All
\n\t\t\t\t\t\t\t\t\tThe weekly newsletter from science writers takes the jargon out of science and puts the fun in!<\/p>\n
Data Point
\n\t\t\t\t\t\t\t\t\tDecoding the headlines with facts, figures, and numbers<\/p>\n
THEdge
\n\t\t\t\t\t\t\t\t\tAt the cutting edge of education and careers<\/p>\n
Health Matters
\n\t\t\t\t\t\t\t\t\tRamya Kannan writes to you on getting to good health, and staying there<\/p>\n
Gender Agenda
\n\t\t\t\t\t\t\t\t\tStories from beyond the binary.<\/p>\n
The Hindu On Books
\n\t\t\t\t\t\t\t\t\tBooks of the week, reviews, excerpts, new titles and features.<\/p>\n
Updated – August 14, 2026 12:59 pm IST – HYDERABAD<\/p>\n
U.S. Food and Drug Administration (U.S. FDA). File
\n | Photo Credit: Getty Images\/iStockphotos<\/p>\n
A formulation manufacturing facility of Aurobindo Pharma subsidiary near Hyderabad has been issued a warning letter by the U.S. Food and Drug Administration (U.S. FDA).<\/p>\n
The action on the facility of Eugia Pharma Specialities, the subsidiary, follows the four observations the regulator had issued in February after an inspection and in May, an Official Action Indicated (OAI) status.<\/p>\n
Subsequent to OAI, the unit has received a warning letter, Aurobindo Pharma said on Firday (August 14, 2026) even as the parent company shares were in the spotlight. Around noon, the shares on BSE were around 1.25% down at \u20b91,636.20 each recovering from a sharper decline when the market opened.<\/p>\n